Farms.com Home   Ag Industry News

China planning to resume U.S. soy imports

China planning to resume U.S. soy imports

Import volumes could reach 8 million tons, a Chinese government official said

By Diego Flammini
Staff Writer
Farms.com

Ships carrying U.S. soybeans could begin sailing to China soon.

The Chinese State Council or cabinet will have the final word on when the country resumes imports of American soybeans, and how much of the commodity China will receive.

Government officials are debating if China should import 5 million tons or 8 million tons. They are also discussing if commercial companies should import an additional 2 million tons and receive reimbursement for the 25 percent tariffs, a government official said, Bloomberg reported.

Details are still unclear if the shipments will resume this month and be taxed, or if they’ll begin after a tariff reduction.

Last year, China accounted for 57 percent of U.S. soybean exports, worth about US$12.4 billion.

As of Oct. 2018, China had only imported about US$3.1 billion worth of U.S soybeans, the U.S. Census Bureau says.

News of any American soybeans arriving at Chinese ports is beneficial for the industry, said John Heisdorffer, chairman of the American Soybean Association.

“We couldn’t be more thrilled if China starts to accept our beans again,” he told Farms.com. “We’ve had almost zero beans going into China for the last three or four months. So, for there to be a little bit of hope that these trade talks appear to be successful is great for American soybean farmers.”

Soybean markets have responded positively to renewed trade discussions between China and the U.S.

After Presidents Jinping and Trump agreed to a trade truce during the G20 in Argentina, soybean prices jumped to US$9.19 per bushel.

Grain markets opened today at US$9.12 per bushel.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.